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Abstract
When the development of chemotherapeutic agents reaches the clinical trial stage, it is nec-
essary to perform drug sensitivity tests quickly in order to select the most promising agents for
the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic
assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5
human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the
MTT assay was 0.673, indicating a relatively good correlation. The correlation was most promi-
nent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611).
However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38
(an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high
degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines
to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT
assay may be more convenient and quickly performed than the HTCA and can replace HTCA
in evaluating the effects of anticancer agents, especially the platinum analogues and anthracy-
clines/anthracenedione.
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SBC-1 SBC-2 SBC-3 ABC-1 EBC-1 SBC-1 SBC-2 SBC-3 ABC-1 EBC-1
doxorubicin 190 235 60 520 2,800 29 69 22 62 70
daunorubicih NO NO 72 NO NO NO NO 35 NO NO
epirubicin NO NO 130 NO NO NO NO 19 NO NO
pirarubicin 98 92 16 120 320 76 74 7 105 156
aclarubicin 92 60 58 85 360 23 14 5 12 14
SM-5887 NO NO 23,600 NO NO NO NO 832 NO NO
ME2303 NO NO 2,400 NO NO NO NO 14 NO NO
KRN8602 NO NO 1,400 NO NO NO NO 45 NO NO
mitoxantrone 210 270 34 180 860 86 140 15 350 440
cisplatin 3,800 6,600 4,830 9,170 84,100 646 2,188 603 1,622 6,310
carboplatin 62,400 51,900 77,100 134,800 606,800 6,500 5,800 4,571 14,000 39,000
254-S 10,200 13,900 14,100 19,500 108,300 1,150 2,000 891 3,000 8,600
NK121 32,400 49,200 23,400 158,000 490,400 2,200 4,000 2,000 5,000 15,600
DWA2114R 95,700 91,300 111,300 186,800 685,800 7,600 17,000 9,800 16,000 80,000
vincristine 673 420 12,400 5,500 NO 8 2 2 2 4
viNOesine 500 NO 5,000 3,450 2,400 2 1 4 2 4
vinblastine 750 420 3,200 2,000 420 4 3 2 2 3
vinorelbine 680 260 1,900 3,280 8,900 53 3 5 4 6
etoposide 315,000 438,000 745,000 820,000 245,000 245 1,202 288 1,549 3,802
irinotecan 55,000 32,000 72,300 200,000 500,000 5,754 2,455 316 665 501
SN-38 20 34 61 81 107 5 3 1 2 2
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obtained whileexponentialgrowth was maintained
［10,12］.
Weperformedthepresentstudytoevaluatethe
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